Affordable Access

deepdyve-link
Publisher Website

Clinical Validation and Performance Evaluation of the Automated Vitros Total Anti-SARS-CoV-2 Antibodies Assay for Screening of Serostatus in COVID-19.

Authors
  • Garnett, Emily1, 2
  • Jung, Joanna1, 2
  • Tam, Estella2
  • Rajapakshe, Deepthi2
  • Cheney, Stephen1
  • Brown, Cameron1
  • Cao, Jing1, 2
  • Muldrew, Kenneth1
  • Singh, Ila1, 2
  • Versalovic, James1, 2
  • Devaraj, Sridevi1, 2
  • 1 Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX.
  • 2 Section of Clinical Chemistry, Division of Laboratory Medicine, Department of Pathology, Texas Children's Hospital, Houston.
Type
Published Article
Journal
American Journal of Clinical Pathology
Publisher
Oxford University Press
Publication Date
Nov 04, 2020
Volume
154
Issue
6
Pages
742–747
Identifiers
DOI: 10.1093/ajcp/aqaa157
PMID: 32864699
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Evaluation of serostatus against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as an important tool in identification of exposure to coronavirus disease 2019 (COVID-19). We report on the validation of the Vitros Anti-SARS-CoV-2 Total (CoV2T) assay for qualitative serologic testing of SARS-CoV-2 antibodies. We performed validation studies according to Commission of Office Laboratories Accreditation guidelines, using samples previously tested for SARS-CoV-2 by reverse transcription-polymerase chain reaction (RT-PCR). We evaluated precision, analytical interferences, and cross-reactivity with other viral infections; evaluated concordance with molecular and other serologic testing; and evaluated seroconversion. The Vitros CoV2T assay exhibited acceptable precision and did not exhibit cross-reactivity with other acute respiratory virus infections. The CoV2T assay exhibited 100% negative predictive agreement (56/56) and 71% positive predictive agreement (56/79) with RT-PCR across all patient samples and was concordant with other serologic assays. Concordance with RT-PCR was 97% more than 7 days after symptom onset. The CoV2T assay was robust to icterus and lipemia but had interference from significant hemolysis. The Vitros CoV2T assay was successfully validated in our laboratory. We anticipate it will be a useful tool in screening for exposure to SARS-CoV-2; however, the use of the CoV2T and other serologic assays in the clinical management of patients with COVID-19 is unknown and must be evaluated in future studies. © American Society for Clinical Pathology, 2020. All rights reserved. For permissions, please e-mail: [email protected]

Report this publication

Statistics

Seen <100 times